April 21, 2022 7:53am
Wednesday’s resistance crushed some share pricing weight
Pre-open indications: 4 Upside Indications, 2 Downside Indications and 1 Pimp/Pump/Promote
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Just the facts … I ask questions and note the indications of what could happen …
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.69% (+241 points), S&P futures are UP +0.89% (+39 points) and NASDAQ futures are UP +1.23% (+172 points) early in the pre-open
Stock futures rose in pre-open trading Thursday even though awaiting a policy speech from Fed Chair Powell at 1 p.m.,
European stocks traded slightly higher as war between Russia and Ukraine overwhelms expectation,
Asia-Pacific stocks were mixed as investors continue to watch China’s Covid-19 situation along with moves in the Japanese yen.
Henry’omics:
Indexes were mixed on Wednesday as some failures of Q1 earnings results scaring investors away from buying ahead of earnings’ reporting.
The Dow closed UP +249.79 points (+0.72%); the S&P closed DOWN -2.75 points (-0.06%) while the Nasdaq closed DOWN -166.59 points (-1.22%)
Economic Data Docket: Weekly jobless claims, investors were looking to a speech from Powell, who will talk at 1 p.m. ET during the International Monetary Fund Debate on the Global Economy.
Last night’s RegMed Investors’ (RMi) closing bell post: “low volume lethargy enables fatigued sentiment hampering some share pricings. By means of yesterday’s short-lived high and today’s low volume melted showed the Icarus metaphor of danger.” … https://www.regmedinvestors.com/articles/12397
Ebb and flow –
Q2/22 – 1 holiday, 4 positive and 9 negative close
Q1/22:
· March – 13 negative and 10 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Upside Indications:
Beam Therapeutics (BEAM) closed down -$0.93 to $43.77 after Tuesday’s +$0.72 and Monday’s -$2.42 with a positive +$2.18 or +4.98% pre-open indication,
Caribou Biosciences (CRBU) closed up+$0.02 to $8.20 with a positive +$0.35 or +4.27% pre-open indication,
CRISPR Therapeutics (CRSP) closed down -$1.38 to $57.58 after Tuesday’s +$0.22 with a positive +$0.67 or +1.16% pre-open indication,
Editas Medicine (EDIT) closed down -$0.41 to $15.37 after Tuesday’s +$0.07 with a positive +$0.58 or +3.77% pre-open indication,
Downside Indications:
Alnylam Pharmaceuticals (ALNY) closed up +$6.75 to $167.95 after Tuesday’s $161.20 and Monday’s $156.68 with a negative -$6.31 or -3.76% pre-open indication
Global Blood Therapeutics (GBT) closed up+$0.97 to $35.66 with a negative -$0.66 or -1.85% pre-open indication,
Pimp/Pump and Promote:
Biostage (BSTG) closed down-$0.48 to $5.50 with 1,131 shares traded after Tuesday’s +$0.48 with 1,168 shares traded after Monday -$0.48 with 2,873 shares traded and last Thursday’s -$0.02 to $5.98.
- WARNING: WHY BUY this equity with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a precarious financial position dependent on a possible cash infusion? Also, WHY the pump of the volume to gain share appreciation – they have to reverse the multiple private placements (the priciest was $4.71) for a potential/proposed stock offering.
The BOTTOM LINE: Yesterday, the Nasdaq composite hit resistance at its 200-day line and reversed lower.
I try to keep it simple … and short!
To expect a payday; volatility and low volume are part of the equation which could set-up BUY/SELL opportunities.
Investors should consider taking at least partial profits quickly on winners to avoid round-tripping moves.
I am still, in the here and now, the cell and gene therapy sector will continue to “flutter”; we are about to enter the earnings’ zone!
Earnings’ season is upon us as Alnylam Pharmaceuticals (ALNY) reports Thursday,4/28 followed so far by Sage Therapeutics (SAGE) on 5/3 and AxoGen (AXGN) on 5/4.
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Share pricing intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
